-
Mashup Score: 0Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies - 10 month(s) ago
Anticancer immunotherapies, such as immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells, have improved outcomes for patients with a variety of malignancies. However, most patients either do not initially respond or do not exhibit durable responses due to primary or adaptive/acquired immune resistance mechanisms of the tumor microenvironment. These…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors - 10 month(s) ago
Background Immune checkpoint inhibitors (ICIs) have dramatically improved survival in patients with cancer but are often accompanied by severe immune-related adverse events (irAEs), which can sometimes be irreversible. Insulin-dependent diabetes is a rare, but life-altering irAE. Our purpose was to determine whether recurrent somatic or germline mutations are observed in patients who develop…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Germline genetics implicated in type I diabetes from immunotherapy @jitcancer @Yale: - 9/13pts w ICI-DM had NLRC5 germline variants v controls by whole exome - unique mechanism not seen in traditional type I DM @OncoAlert #IOTox https://t.co/IUz2KTcgkH
-
-
Mashup Score: 3
Cytokine storm induced by anti-human epidermal growth factor receptor-2 (HER2) therapies has not been reported. We report a patient with breast cancer treated with trastuzumab/pertuzumab who developed severe biventricular dysfunction and cardiogenic shock (CS) 6 months after starting double anti-HER2 therapy. The CS was accompanied by severe systemic inflammation, and cardiac MRI (cMRI) showed…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies. Interesting case- may have implications as we develop anti-HER2 cell therapies (CAR/NK) @jitcancer @OncoAlert @peters_solange https://t.co/iwsJMKAjeO
-
-
Mashup Score: 3132 Racial differences in TMB measures between paired tumor/normal and tumor-only sequencing across endometrial, bladder, and non-small cell lung cancers - 10 month(s) ago
Background Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of a tumor, is routinely used as a predictive biomarker for immunotherapy response in metastatic cancer patients. Sequencing of paired tumor and normal specimens allows for correction of TMB estimates with patient-specific germline variants. For tumor only assays, TMB estimates are corrected using…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Racial differences in TMB measures b/w paired tumor/normal & tumor-only sequencing across endometrial, bladder & non-small cell lung cancers [Nov 7, 2022] @ribozyme et al. @JITC #SITC22 Abs 132 https://t.co/1g4yPP9zjY #PrecisionMedicine #ImmunoOnc #gyncsm #blcsm @lcsm @TempusLabs
-
-
Mashup Score: 5
Liquid biopsies are gaining momentum as minimally invasive means for cancer detection, characterization, monitoring, and interception. Composed of five expert-opinion review articles and five accompanying expert-physician viewpoints, this Journal for ImmunoTherapy of Cancer Special Review Series focuses on capturing and synthesizing the current state of science of liquid biopsies and their…
Categories: Latest Headlines, Oncologists2Tweet-
RT @ValsamoA: Read all articles in the @jitcancer #liquidbiopsy series: https://t.co/y7uvVfmTYR https://t.co/CqXPNpoplg
-
-
Mashup Score: 28Vaccinating against cancer: getting to prime time - 11 month(s) ago
Immunotherapies, such as immune checkpoint inhibitors, cellular therapies, and T-cell engagers, have fundamentally changed our approach to treating cancer. However, successes with cancer vaccines have been more difficult to realize. While vaccines against specific viruses have been widely adopted to prevent the development of cancer, only two vaccines can improve survival in advanced disease:…
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @jitcancer: New #JITC review: Vaccinating against cancer: getting to prime time https://t.co/2TMFmzCekH @gulleyj1 @lawfong https://t.co/…
-
-
Mashup Score: 1Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer - 11 month(s) ago
Advanced gynecologic cancers have historically lacked effective treatment options. Recently, immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug Administration for the treatment of cervical cancer and endometrial cancer, offering durable responses for some patients. In addition, many immunotherapy strategies are under investigation for the treatment of earlier stages of…
Categories: Hem/Oncs, Latest HeadlinesTweet-
New @sitcancer clinical practice guideline on #immunotherapy for the treatment of gynecologic cancer in @jitcancer Honored to have been able to contribute to this effort #IO #CIM23 https://t.co/NbVtOnWM5t
-
-
Mashup Score: 0Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer - 11 month(s) ago
Gastrointestinal (GI) cancers, including esophageal, gastroesophageal junction, gastric, duodenal and distal small bowel, biliary tract, pancreatic, colon, rectal, and anal cancer, comprise a heterogeneous group of malignancies that impose a significant global burden. Immunotherapy has transformed the treatment landscape for several GI cancers, offering some patients durable responses and…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer https://t.co/fYrKK2X02v
-
-
Mashup Score: 0Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer - 11 month(s) ago
Gastrointestinal (GI) cancers, including esophageal, gastroesophageal junction, gastric, duodenal and distal small bowel, biliary tract, pancreatic, colon, rectal, and anal cancer, comprise a heterogeneous group of malignancies that impose a significant global burden. Immunotherapy has transformed the treatment landscape for several GI cancers, offering some patients durable responses and…
Categories: Hem/Oncs, Latest HeadlinesTweet-
.@sitcancer Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. https://t.co/7ypJAD8qow @jitcancer
-
-
Mashup Score: 12Vaccinating against cancer: getting to prime time - 11 month(s) ago
Immunotherapies, such as immune checkpoint inhibitors, cellular therapies, and T-cell engagers, have fundamentally changed our approach to treating cancer. However, successes with cancer vaccines have been more difficult to realize. While vaccines against specific viruses have been widely adopted to prevent the development of cancer, only two vaccines can improve survival in advanced disease:…
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @jitcancer: New #JITC review: Vaccinating against cancer: getting to prime time https://t.co/2TMFmzCekH @gulleyj1 @lawfong https://t.co/…
-
Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies https://t.co/k73QteM8c2